Aethlon Medical, Inc. has announced its financial results for the fiscal fourth quarter ended March 31, 2025. The company reported a net loss attributable to common stockholders of approximately $13.4 million for the period, compared to a net loss of about $12.2 million in the same period the previous year. The comprehensive loss for the quarter was approximately $13.4 million, up from $12.2 million the previous year. Aethlon Medical also reported a decrease in operating expenses for the fiscal year ended March 31, 2025. Operating expenses amounted to approximately $9.3 million, representing a reduction of $3.3 million or approximately 26% compared to $12.6 million for the previous fiscal year. This decline was primarily due to a reduction in payroll and related expenses, professional fees, and general and administrative costs, with payroll expenses alone reduced by about $1.3 million. As of March 31, 2025, Aethlon Medical had a cash balance of approximately $5.5 million. The company has streamlined its operations, reducing operating expenses to focus on its clinical and regulatory goals effectively.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。